Cardiac Phenotype of Prehypertrophic Fabry Disease

Sabrina Nordin, Rebecca Kozor, Shanat Baig, Amna Abdel-Gadir, Katia Medina-Menacho, Stefania Rosmini, Gabriella Captur, Michel Tchan, Tarekegn Geberhiwot, Elaine Murphy, Robin Lachmann, Uma Ramaswami, Nicola C Edwards, Derralynn Hughes, Richard P Steeds, James C Moon, Sabrina Nordin, Rebecca Kozor, Shanat Baig, Amna Abdel-Gadir, Katia Medina-Menacho, Stefania Rosmini, Gabriella Captur, Michel Tchan, Tarekegn Geberhiwot, Elaine Murphy, Robin Lachmann, Uma Ramaswami, Nicola C Edwards, Derralynn Hughes, Richard P Steeds, James C Moon

Abstract

Background: Fabry disease (FD) is a rare and treatable X-linked lysosomal storage disorder. Cardiac involvement determines outcomes; therefore, detecting early changes is important. Native T1 by cardiovascular magnetic resonance is low, reflecting sphingolipid storage. Early phenotype development is familiar in hypertrophic cardiomyopathy but unexplored in FD. We explored the prehypertrophic cardiac phenotype of FD and the role of storage.

Methods and results: A prospective, international multicenter observational study of 100 left ventricular hypertrophy-negative FD patients (mean age: 39±15 years; 19% male) and 35 age- and sex-matched healthy volunteers (mean age: 40±14 years; 25% male) who underwent cardiovascular magnetic resonance, including native T1 and late gadolinium enhancement, and 12-lead ECG. In FD, 41% had a low native T1 using a single septal region of interest, but this increased to 59% using a second slice because early native T1 lowering was patchy. ECG abnormalities were present in 41% and twice as common with low native T1 (53% versus 24%; P=0.005). When native T1 was low, left ventricular maximum wall thickness, indexed mass, and ejection fraction were higher (maximum wall thickness 9±1.5 versus 8±1.4 mm, P<0.005; indexed left ventricular mass 63±10 versus 58±9 g/m2, P<0.05; and left ventricular ejection fraction 73±8% versus 69±7%, P<0.01). Late gadolinium enhancement was more likely when native T1 was low (27% versus 6%; P=0.01). FD had higher maximal apical fractal dimensions compared with healthy volunteers (1.27±0.06 versus 1.24±0.04; P<0.005) and longer anterior mitral valve leaflets (23±2 mm versus 21±3 mm; P<0.005).

Conclusions: There is a detectable prehypertrophic phenotype in FD consisting of storage (low native T1), structural, functional, and ECG changes.

Keywords: Fabry disease; hypertrophy, left ventricular; magnetic resonance imaging; phenotype.

© 2018 The Authors.

Figures

Figure 1.
Figure 1.
A patient with obvious but missed low native T1.Top: The usual approach is to draw one region of interest (ROI) in a single short-axis (SA) slice. This generated a normal native T1 (932 ms). Note, however, there is blue myocardium in the second, unmeasured slice. By drawing other ROIs on both slices (bottom), the low native T1 is captured.
Figure 2.
Figure 2.
Spectrum of native T1 in left ventricular hypertrophy–negative Fabry disease with corresponding late gadolinium enhancement (LGE) images. Patient 1: Normal native T1 in both basal and mid short axis (SA). Patient 2: Patchy low native T1 in the lateral walls. Patient 3: Patchy low native T1 mainly in both SA slices. Patient 4: Patchy low native T1 in the mid SA septum but normal native T1 in basal SA. Patient 5: low native T1 all across both SA.
Figure 3.
Figure 3.
Comparison of ECG abnormalities between low native T1 and normal native T1 Fabry disease subgroups. AF indicates atrial fibrillation; BBB, bundle branch block; and VE, ventricular ectopics.
Figure 4.
Figure 4.
Normal versus abnormal ECG and late gadolinium enhancement (LGE)–positive vs LGE-negative in the low native T1 and normal native T1 Fabry disease (FD) subgroups showing ECG abnormalities are found in 76% vs 24% (P=0.005) and LGE in 87% versus 13% (P=0.01).
Figure 5.
Figure 5.
Example of a Fabry disease (FD) patient with low native T1 and no late gadolinium enhancement (LGE) with abnormal ECG (T-wave inversion in leads III, aVF, V4 through V6). Anterior mitral valve leaflet (AMVL) elongation (24 mm) and hypertrabeculation (fractal dimensionsmaxapical 1.32) were also present; these latter 2 features, however, are native T1-independent.

References

    1. Zarate YA, Hopkin RJ. Fabry’s disease. Lancet. 2008;372:1427–1435. doi: 10.1016/S0140-6736(08)61589-5.
    1. Waldek S, Patel MR, Banikazemi M, Lemay R, Lee P. Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry. Genet Med. 2009;11:790–796. doi: 10.1097/GIM.0b013e3181bb05bb.
    1. Baig S, Edwards N, Kotecha D, Liu B, Nordin S, Kozor R, Moon JC, Geberhiwot T, Steeds RP. Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review and identification of risk factors in clinical practice [published online ahead of print October 17, 2017]. Europace. doi: 10.1093/europace/eux261. . Accessed April 24, 2018.
    1. Patel MR, Cecchi F, Cizmarik M, Kantola I, Linhart A, Nicholls K, Strotmann J, Tallaj J, Tran TC, West ML, Beitner-Johnson D, Abiose A. Cardiovascular events in patients with Fabry disease natural history data from the Fabry registry. J Am Coll Cardiol. 2011;57:1093–1099. doi: 10.1016/j.jacc.2010.11.018.
    1. Nordin S, Kozor R, Bulluck H, Castelletti S, Rosmini S, Abdel-Gadir A, Baig S, Mehta A, Hughes D, Moon JC. Cardiac Fabry disease with late gadolinium enhancement is a chronic inflammatory cardiomyopathy. J Am Coll Cardiol. 2016;68:1707–1708. doi: 10.1016/j.jacc.2016.07.741.
    1. Desnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WR. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138:338–346.
    1. Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, Feliciani C, Shankar SP, Ezgu F, Amartino H, Bratkovic D, Feldt-Rasmussen U, Nedd K, Sharaf El Din U, Lourenco CM, Banikazemi M, Charrow J, Dasouki M, Finegold D, Giraldo P, Goker-Alpan O, Longo N, Scott CR, Torra R, Tuffaha A, Jovanovic A, Waldek S, Packman S, Ludington E, Viereck C, Kirk J, Yu J, Benjamin ER, Johnson F, Lockhart DJ, Skuban N, Castelli J, Barth J, Barlow C, Schiffmann R. Treatment of Fabry’s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375:545–555. doi: 10.1056/NEJMoa1510198.
    1. Weidemann F, Niemann M, Breunig F, Herrmann S, Beer M, Störk S, Voelker W, Ertl G, Wanner C, Strotmann J. Long-term effects of enzyme replacement therapy on Fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation. 2009;119:524–529. doi: 10.1161/CIRCULATIONAHA.108.794529.
    1. Brakch N, Dormond O, Bekri S, Golshayan D, Correvon M, Mazzolai L, Steinmann B, Barbey F. Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease. Eur Heart J. 2010;31:67–76. doi: 10.1093/eurheartj/ehp387.
    1. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, Leed PJ, Elliott PM. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J. 2003;24:2151–2155.
    1. Moon JC, Sheppard M, Reed E, Lee P, Elliott PM, Pennell DJ. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson. 2006;8:479–482.
    1. Krämer J, Niemann M, Störk S, Frantz S, Beer M, Ertl G, Wanner C, Weidemann F. Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease. Am J Cardiol. 2014;114:895–900. doi: 10.1016/j.amjcard.2014.06.019.
    1. Kozor R, Grieve SM, Tchan MC, Callaghan F, Hamilton-Craig C, Denaro C, Moon JC, Figtree GA. Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR. Heart. 2016;102:298–302. doi: 10.1136/heartjnl-2015-308494.
    1. Niemann M, Herrmann S, Hu K, Breunig F, Strotmann J, Beer M, Machann W, Voelker W, Ertl G, Wanner C, Weidemann F. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging. 2011;4:592–601. doi: 10.1016/j.jcmg.2011.01.020.
    1. Pica S, Sado DM, Maestrini V, Fontana M, White SK, Treibel T, Captur G, Anderson S, Piechnik SK, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Kellman P, Elliott PM, Herrey AS, Moon JC. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2014;16:99. doi: 10.1186/s12968-014-0099-4.
    1. Thompson RB, Chow K, Khan A, Chan A, Shanks M, Paterson I, Oudit GY. T1 mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex. Circ Cardiovasc Imaging. 2013;6:637–645. doi: 10.1161/CIRCIMAGING.113.000482.
    1. Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, Fontana M, Maestrini V, Flett AS, Robson MD, Lachmann RH, Murphy E, Mehta A, Hughes D, Neubauer S, Elliott PM, Moon JC. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6:392–398. doi: 10.1161/CIRCIMAGING.112.000070.
    1. Havranek S, Linhart A, Urbanova Z, Ramaswami U. Early cardiac changes in children with Anderson-Fabry disease. JIMD Rep. 2013;11:53–64. doi: 10.1007/8904_2013_222.
    1. Namdar M, Steffel J, Vidovic M, Brunckhorst CB, Holzmeister J, Lüscher TF, Jenni R, Duru F. Electrocardiographic changes in early recognition of Fabry disease. Heart. 2011;97:485–490. doi: 10.1136/hrt.2010.211789.
    1. Coats CJ, Parisi V, Ramos M, Janagarajan K, O’Mahony C, Dawnay A, Lachmann RH, Murphy E, Mehta A, Hughes D, Elliott PM. Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with Anderson-Fabry disease. Am J Cardiol. 2013;111:111–117. doi: 10.1016/j.amjcard.2012.08.055.
    1. Tanislav C, Guenduez D, Liebetrau C, Giese AK, Eichler S, Sieweke N, Speth M, Bauer T, Hamm C, Rolfs A. Cardiac troponin I: a valuable biomarker indicating the cardiac involvement in Fabry disease. PLoS One. 2016;11:e0157640. doi: 10.1371/journal.pone.0157640.
    1. Captur G, Lopes LR, Mohun TJ, Patel V, Li C, Bassett P, Finocchiaro G, Ferreira VM, Esteban MT, Muthurangu V, Sherrid MV, Day SM, Canter CE, McKenna WJ, Seidman CE, Bluemke DA, Elliott PM, Ho CY, Moon JC. Prediction of sarcomere mutations in subclinical hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2014;7:863–871. doi: 10.1161/CIRCIMAGING.114.002411.
    1. Maceira AM, Prasad SK, Khan M, Pennell DJ. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2006;8:417–426.
    1. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, Schulz-Menger J, Schelbert EB Society for Cardiovascular Magnetic Resonance Imaging; Cardiovascular Magnetic Resonance Working Group of the European Society of Cardiology. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92. doi: 10.1186/1532-429X-15-92.
    1. Captur G, Gatehouse P, Keenan KE, Heslinga FG, Bruehl R, Prothmann M, Graves MJ, Eames RJ, Torlasco C, Benedetti G, Donovan J, Ittermann B, Boubertakh R, Bathgate A, Royet C, Pang W, Nezafat R, Salerno M, Kellman P, Moon JC. A medical device-grade T1 and ECV phantom for global T1 mapping quality assurance-the T1 mapping and ECV standardization in cardiovascular magnetic resonance (T1MES) program. J Cardiovasc Magn Reson. 2016;18:58. doi: 10.1186/s12968-016-0280-z.
    1. Kozor R, Nordin S, Treibel TA, Rosmini S, Castelletti S, Fontana M, Captur G, Baig S, Steeds RP, Hughes D, Manisty C, Grieve SM, Figtree GA, Moon JC. Insight into hypertrophied hearts: a cardiovascular magnetic resonance study of papillary muscle mass and T1 mapping. Eur Heart J Cardiovasc Imaging. 2017;18:1034–1040. doi: 10.1093/ehjci/jew187.
    1. Kozor R, Callaghan F, Tchan M, Hamilton-Craig C, Figtree GA, Grieve SM. A disproportionate contribution of papillary muscles and trabeculations to total left ventricular mass makes choice of cardiovascular magnetic resonance analysis technique critical in Fabry disease. J Cardiovasc Magn Reson. 2015;17:22. doi: 10.1186/s12968-015-0114-4.
    1. Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, Haas TS, Udelson JE, Manning WJ, Maron BJ. Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. Circulation. 2011;124:40–47. doi: 10.1161/CIRCULATIONAHA.110.985812.
    1. Captur G, Radenkovic D, Li C, Liu Y, Aung N, Zemrak F, Tobon-Gomez C, Gao X, Elliott PM, Petersen SE, Bluemke DA, Friedrich MG, Moon JC. Community delivery of semiautomated fractal analysis tool in cardiac MR for trabecular phenotyping. J Magn Reson Imaging. 2017;46:1082–1088. doi: 10.1002/jmri.25644.
    1. Patel V, O’Mahony C, Hughes D, Rahman MS, Coats C, Murphy E, Lachmann R, Mehta A, Elliott PM. Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry Disease. Heart. 2015;101:961–966. doi: 10.1136/heartjnl-2014-306782.
    1. Weidemann F, Niemann M, Störk S, Breunig F, Beer M, Sommer C, Herrmann S, Ertl G, Wanner C. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med. 2013;274:331–341. doi: 10.1111/joim.12077.
    1. Captur G, Ho CY, Schlossarek S, Kerwin J, Mirabel M, Wilson R, Rosmini S, Obianyo C, Reant P, Bassett P, Cook AC, Lindsay S, McKenna WJ, Mills K, Elliott PM, Mohun TJ, Carrier L, Moon JC. The embryological basis of subclinical hypertrophic cardiomyopathy. Sci Rep. 2016;6:27714. doi: 10.1038/srep27714.
    1. Schmied C, Nowak A, Gruner C, Olinger E, Debaix H, Brauchlin A, Frank M, Reidt S, Monney P, Barbey F, Shah D, Namdar M. The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy. Heart. 2016;102:1309–1314. doi: 10.1136/heartjnl-2015-308897.
    1. Aryana A, Fifer MA, Ruskin JN, Mela T. Short PR interval in the absence of preexcitation: a characteristic finding in a patient with Fabry disease. Pacing Clin Electrophysiol. 2008;31:782–783. doi: 10.1111/j.1540-8159.2008.01088.x.
    1. Jastrzebski M, Bacior B, Dimitrow PP, Kawecka-Jaszcz K. Electrophysiological study in a patient with Fabry disease and a short PQ interval. Europace. 2006;8:1045–1047. doi: 10.1093/europace/eul121.
    1. O’Mahony C, Coats C, Cardona M, Garcia A, Calcagnino M, Murphy E, Lachmann R, Mehta A, Hughes D, Elliott PM. Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace. 2011;13:1781–1788. doi: 10.1093/europace/eur267.
    1. Pochis WT, Litzow JT, King BG, Kenny D. Electrophysiologic findings in Fabry’s disease with a short PR interval. Am J Cardiol. 1994;74:203–204.
    1. Ikari Y, Kuwako K, Yamaguchi T. Fabry’s disease with complete atrioventricular block: histological evidence of involvement of the conduction system. Br Heart J. 1992;68:323–325.
    1. Sheppard MN, Cane P, Florio R, Kavantzas N, Close L, Shah J, Lee P, Elliott P. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. Cardiovasc Pathol. 2010;19:293–301. doi: 10.1016/j.carpath.2009.05.003.
    1. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart. 2007;93:528–535. doi: 10.1136/hrt.2005.063818.
    1. Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta AB. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008;94:153–158. doi: 10.1136/hrt.2006.104026.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe